Lifting limits: liposomal delivery of chemotherapy for secondary AML with CPX-351

Jeffrey Lancet

Elderly patients with secondary acute myeloid leukemia (AML) typically had poor outcomes following standard chemotherapy treatment. However, this changed in August 2017 with the approval of CPX-351 following results from the Phase III trial (NCT01696084), which indicated that it should become the standard of care for therapy-related AML and AML with myelodysplasia-related changes, which are typically hard to treat. Here, Jeffrey Lancet, MD, of the Moffitt Cancer Center, Tampa, FL, gives us an overview of this treatment, which comprises the liposomal delivery of a combination of cytarabine (ara-C) and daunorubicin at a specific molar ratio. Dr Lancet explains the benefits of using this delivery system, highlighting the results seen and emphasizing that this is the first time that this approach has been utilized this effectively in cancer. This video was recorded at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL.

Share this video